More: National Comprehensive Cancer Network (NCCN) 13th Annual Conference

Reducing Treatment-Related Toxicity in Patients With Advanced Colorectal Cancer CME

March 5 - 9, 2008, Hollywood, Florida

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the National Comprehensive Cancer Network.

Release Date: March 28, 2008; Valid for credit through March 28, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details

Contents of This CME Activity

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the National Comprehensive Cancer Network. These materials and the related activity are not sanctioned by the National Comprehensive Cancer Network or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Roche
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review current standard treatment regimens -- and their associated toxicities -- for patients with advanced colorectal cancer
  2. Discuss treatment-associated toxicities with a bearing on the clinician's ability to administer effective therapy and affecting the patient's quality of life
  3. Describe ongoing and planned trials that further address issues of treatment-related toxicities in the setting of advanced colorectal cancer
Authors and Disclosures

Paul F. Engstrom, MD
Disclosure: Paul F. Engstrom, MD, has disclosed no relevant financial relationships.


Leonard B. Saltz, MD
Disclosure: Leonard B. Saltz, MD, has disclosed that he has received grants for clinical research from Amgen, Bayer, Bristol-Myers Squibb, Genentech, ImClone, Merck, Pfizer, Roche, and Taiho Pharmaceuticals, and that he has served as an advisor or consultant to Genentech, ImClone, Merck, and YM BioSciences.


Michael Choti, MD
Disclosure: Michael Choti, MD, has disclosed no relevant financial relationships.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.